M.D. Anderson Cancer Center Newswire (Page 2)

M.D. Anderson Cancer Center Newswire (Page 2)

Comprehensive Real-Time News Feed for M.D. Anderson Cancer Center. (Page 2)

Results 21 - 40 of 1,227 in M.D. Anderson Cancer Center

  1. HEB and MD Anderson team up to fight cancer Read StoryRead the original story w/Photo

    Friday Aug 19 | KIII

    B is joining the fight to end cancer and they need your help. The Texas based grocery store is asking customers to donate to M.D. Anderson Cancer Center.

    Comment?

  2. H-E-B and M.D. Anderson team up against cancerRead the original story w/Photo

    Friday Aug 19 | KIII

    B is joining the fight to end cancer and they need your help. The Texas based grocery store is asking customers to donate to M.D. Anderson Cancer Center.

    Comment?

  3. H-E-B and the MD Anderson Cancer Center are teaming up to strike out cancer.Read the original story w/Photo

    Wednesday Aug 17 | KRISTV.COM Corpus Christi

    On Friday, they'll launch a statewide campaign to raise funds for MD Anderson's research, prevention and education programs. H-E-B customers will be able to make donations of one to five dollars, when they check out at the register.

    Comment?

  4. Remedy Pharmaceuticals, Inc.??? Edema And Neuro-Inflammation Advisory ...Read the original story

    Wednesday Aug 17 | BioSpace

    Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced the successful conclusion of a two-day scientific advisory board meeting in which a distinguished panel of experts provided recommendations on promising indications for the Company to consider pursuing in addition to its current programs.

    Comment?

  5. Vortex Biosciences Appoints Leading Experts to Newly Formed Scientific Advisory BoardRead the original story

    Thursday Aug 18 | PRWeb

    Vortex Biosciences , provider of circulating tumor cell enrichment systems, today announced the appointment of leading experts to its newly formed Scientific Advisory Board . The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.

    Comment?

  6. Reproducibility in Personalized Medicine Research WorkshopRead the original story

    Wednesday Aug 17 | American Statistical Association

    During the past decade, one of the most notable transformations in science has been the availability of large and diverse sets of data. This trend has been accompanied by the increased use of machine learning and statistical techniques to classify patients and optimize treatments in precision medicine.

    Comment?

  7. Oncoceutics Awarded FDA Orphan Grant For ONC201 Multiple Myeloma TrialRead the original story

    Tuesday Aug 16 | BioSpace

    Oncoceutics announced that it has been awarded an orphan grant from the U.S. Food and Drug Administration to evaluate its lead molecule, ONC201, a selective antagonist of DRD2 that belongs to the superfamily of G protein-coupled receptors , in a multiple myeloma clinical trial. The award totals $1.7 million in funding to support a Phase II program with ONC201 in relapsed/refractory multiple myeloma.

    Comment?

  8. Nation's Top-Ranked Cancer Hospital has Local TiesRead the original story

    Tuesday Aug 16 | PRWeb

    The University of Texas MD Anderson Cancer Center, Summit Medical Group MD Anderson Cancer Center's clinical partner, recently was named the nation's No. 1 hospital for cancer care, as ranked by U.S. News & World Report's "Best Hospitals" annual survey.

    Comment?

  9. ARMO BioSciences Announces Publication Of AM0010 Clinical Data In Advanced Solid Tumor Patients InRead the original story

    Monday Aug 15 | BioSpace

    The peer-review article titled "Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 in Patients with Advanced Solid Tumors" was first published today in the online version of the JCO . "The results of this study show exciting early signs of efficacy, with objective and durable responses achieved in advanced cancer patients who were treated with this single agent," said MD Anderson Cancer Center and lead author of the JCO publication.

    Comment?

  10. The 3rd Annual US Focus on Myeloproliferative Neoplasms and...Read the original story w/Photo

    Tuesday Aug 16 | PRWeb

    Because recent discoveries have the potential to change the paradigm for how both MPN and MDS are diagnosed and treated, it is imperative that HCPs are provided an expert review for optimal integration into everyday clinical practice. Educational, informative and clinically-relevant, the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes will be held at the Westin Alexandria on August 26-27, 2016.

    Comment?

  11. New study uncovers how DNA copy number aberrations impact tumor formation and growthRead the original story w/Photo

    Monday Aug 15 | Medical News

    As with most cancers, triple-negative breast cancer cells have abnormal amounts of chromosomes or DNA copy number aberrations in their genomes. A new study used single cell sequencing technology to provide previously unknown details about how and when CNAs impact tumor formation and growth, information that may have significant implications for diagnosis and treatment.

    Comment?

  12. 'Bursts' of chromosome changes fuel breast cancer tumor growthRead the original story w/Photo

    Monday Aug 15 | PhysOrg Weblog

    Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia As with most cancers, triple-negative breast cancer cells have abnormal amounts of chromosomes or DNA copy number aberrations in their genomes.

    Comment?

  13. Making Cancer History(r): Free Seminar Comes to AustinRead the original story

    Monday Aug 15 | Newswise

    The University of Texas MD Anderson Cancer Center brings its signature Making Cancer HistoryA seminar to Austin, 11:30 a.m. to 1 p.m., Monday, Sept. 12, at the AT&T Executive Education and Conference Center, 1900 University Ave. Renowned experts from the nation's No.

    Comment?

  14. Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2016Read the original story w/Photo

    Jun 30, 2016 | Market Wire

    ... of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced its financial and operating results for the second quarter ended June 30, 2016. Successful ...

    Comment?

  15. Two new drugs show promise for patients with aggressive breast cancerRead the original story w/Photo

    Friday Aug 12 | PhysOrg Weblog

    Patients with aggressive subtypes of locally-advanced breast cancer may have new treatment options on the horizon, according to two reports published in July in the New England Journal of Medicine . Results of two different investigational arms of a multi-drug phase II trial conducted in part by researchers at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center, show that use of new targeted therapies neratinib or a combination of veliparib and carboplatin improves outcomes, when used in addition to standard chemotherapy before surgery for patients with HER2-positive and triple-negative breast cancer, respectively.

    Comment?

  16. Immune analysis of on-treatment longitudinal biopsies predicts response to melanoma immunotherapyRead the original story w/Photo

    Friday Aug 12 | Medical News Today

    Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. Analysis of biopsies before treatment did not indicate who would respond in this unique longitudinal study of 53 melanoma patients treated with two immune checkpoint inhibitors between October 2011 and March 2015.

    Comment?

  17. BCL-2 inhibitor shows promise in AML patientsRead the original story w/Photo

    Thursday Aug 11 | Medical News

    Bottom Line: Patients whose acute myelogenous leukemia had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax , with complete remissions in some, according to phase II clinical trial data.

    Comment?

  18. Cancer patients who practice yoga experience far less pain and anxietyRead the original story w/Photo

    Thursday Aug 11 | NewsTarget.com

    Many people who practice yoga report that it reduces stress and helps them gain a sense of inner calm. The ancient practice, which combines movement with breath, is being explored by researchers as a way to help cancer patients alleviate symptoms and boost their outlook and quality of life.

    Comment?

  19. DelMar Pharma To Present At TheRead the original story

    Wednesday Aug 10 | BioSpace

    In April 2016, the FDA Office of Orphan Products Development granted orphan drug designation for VAL-083 in the treatment of ovarian cancer. The investigational drug candidate had earlier received an orphan designation for glioma and medulloblastoma in in 2022.

    Comment?

  20. Analysis of biopsies during early treatment predicts patient's response to melanoma immunotherapyRead the original story w/Photo

    Thursday Aug 11 | Medical News

    Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. Analysis of biopsies before treatment did not indicate who would respond in this unique longitudinal study of 53 melanoma patients treated with two immune checkpoint inhibitors between October 2011 and March 2015.

    Comment?